One important problem that may arise during PARP inhibitor treatment is the development of resistance. Even BRCA-deficient mouse tumors were reported to acquire resistance to PARP inhibitors.

由苏州大学第一附属医院妇产科的Fang Wang，Yi Zhang，Jinhua Zhou 团队发表的名为“A novel SIK2 inhibitor SIC-19 exhibits synthetic lethality with PARP ...

The first wave of PARP inhibitors has improved outcomes in people with a variety of solid tumors. However, Idience has identified opportunities to improve the efficacy of existing drugs and ...

Five years AstraZeneca became an oncology trailblazer by getting the first PARP inhibitor class drug Lynparza, approved by the FDA for certain ovarian cancers. Now the UK pharma is aiming to build ...

Currently, five PARP inhibitor drugs are running in clinical trials for approval. All have shown proof of concept success in germline BRCA mutation carriers. Furthermore, several combinations with ...

Ovarian cancer, a deadly gynecologic malignancy, has seen a significant shift in its treatment paradigm with the introduction ...

Newer treatments target pathways like Delta-like ligand 3, poly-ADP-ribose polymerase, and histone deacetylase to address ...

PARP inhibitors, such as olaparib, have demonstrated fantastic results for some men. However, not all men respond to this drug, and for those that do, their cancer eventually develops resistance.

Poly(ADP-ribose) polymerase (PARP) inhibitors (PARPis) are promising cancer treatments because they block a ... eliminate malignant cells depends on several factors that scientists should keep in mind ...

Tesaro is to combine its PARP-inhibitor drug Zejula with Roche’s PD-L1 immunotherapy Tecentriq in clinical trials for metastatic bladder cancer. The alliance is important for Tesaro, which is ...

The combination therapy approval from the US Food and Drug Administration (FDA ... biology and bringing a targeted therapy like a PARP inhibitor will hopefully move the needle.” ...

Nearly half of advanced ovarian cancer patients relapsed after first-line PARP inhibitor maintenance, emphasizing the need for refined postrecurrence strategies. BRCA mutation carriers were more ...